gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.

CD83 molecule

The protein encoded by this gene is a single-pass type I membrane protein and member of the immunoglobulin superfamily of receptors. The encoded protein may be involved in the regulation of antigen presentation. A soluble form of this protein can bind to dendritic cells and inhibit their maturation. Three transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Oct 2011] (from NCBI)
Top mentioned proteins: CD86, CD80, IgM, CAN, IL-10
Papers using CD83 antibodies
Neutrophils mediate immune modulation of dendritic cells through glycosylation-dependent interactions between Mac-1 and DC-SIGN
van Kooyk Yvette et al., In The Journal of Experimental Medicine, 1998
... CD16-biotin and CD83-PE were purchased from BD Biosciences, and CLB-gran/10 (CEACAM1, CD66a) ...
Papers on CD83
Antitumor effect of dendritic cells transfected with prostate-specific membrane antigen recombinant adenovirus on prostate cancer: An in vitro study.
Sui et al., Shenyang, China. In Mol Med Report, Feb 2016
The expression levels of the co-stimulatory molecules, CD80, CD83, CD86 and HLA‑DR, were significantly higher in the Ad‑PSMA‑DC group than in the other two groups (P<0.05).
Avian dendritic cells: phenotype and ontogeny in lymphoid organs.
Olah et al., Budapest, Hungary. In Dev Comp Immunol, Feb 2016
Avian follicular dendritic cells (FDC) highly resemble BSDC, express the CD83, 74.3 and CSF1R molecules, and present antigen in germinal centers.
A case of APDS patient: defects in maturation and function and decreased in vitro anti-mycobacterial activity in the myeloid compartment.
Cancrini et al., Roma, Italy. In Clin Immunol, Jan 2016
An in depth analysis of the myeloid compartment showed an increased expression of CD83 activation marker on monocytes and mono-derived DC cells.
Type II arabinogalactan from Anoectochilus formosanus induced dendritic cell maturation through TLR2 and TLR4.
Lin et al., Wuxue, China. In Phytomedicine, Jan 2016
METHODS AND RESULTS: Exposing DCs to AGAF induces cell maturation, which is characterized by the upregulation of CD86, CD83, CD80, CD40, and MHC class I and class II expression through flow cytometry analysis and morphological change without cytotoxicity.
CD1a+ and CD83+ Langerhans cells are reduced in lower lip squamous cell carcinoma.
Vargas et al., Piracicaba, Brazil. In J Oral Pathol Med, Jan 2016
Immunoreactions against CD1a and CD83 identified immature and mature DCs, respectively.
Cellular and molecular mechanisms in graft-versus-host disease.
Wei et al., Hefei, China. In J Leukoc Biol, Jan 2016
As a therapeutic target, soluble CD83 molecules or antibodies have been demonstrated to have therapeutic effects against graft-versus-host disease, and signaling molecules promote the inflammatory and immune process of graft-versus-host disease .
Immune responses of dendritic cells combined with tumor-derived autophagosome vaccine on hepatocellular carcinoma.
Wang et al., Nanjing, China. In Chin J Cancer Res, Dec 2015
RESULTS: DRibbles significantly induced the expression of CD80, CD83, CD86 and HLA-DR on DCs.
Class-switched memory B cells remodel BCRs within secondary germinal centers.
McHeyzer-Williams et al., Los Angeles, United States. In Nat Immunol, Mar 2015
At the clonal and subclonal levels, single-cell expression of the genes encoding the costimulatory molecule CD83 and the DNA polymerase Polη segregated the secondary GC transcriptional program into four stages that regulated divergent mechanisms of memory BCR evolution.
tTregs, pTregs, and iTregs: similarities and differences.
Thornton et al., Bethesda, United States. In Immunol Rev, 2014
Interleukin-10 (IL-10) plays an important role in the suppressive function of antigen-specific iTregs by controlling the expression of MARCH1 and CD83 on the DC.
Primary cutaneous langerhans cell sarcoma: a report of four cases and review of the literature.
Magro et al., Winston-Salem, United States. In Am J Dermatopathol, 2013
Phenotypic studies revealed positivity for CD4, CD1a, and S100 in all and variable staining for langerin, lysozyme, CD83, CD31, and CD14.
Deciphering the message broadcast by tumor-infiltrating dendritic cells.
Tel et al., Nijmegen, Netherlands. In Am J Pathol, 2012
The activation status of DCs is based on the expression of CD83, DC-SIGN, and DC-LAMP, which are nonspecific markers of DC maturation.
Meta-analysis identifies nine new loci associated with rheumatoid arthritis in the Japanese population.
Yamamoto et al., Yokohama, Japan. In Nat Genet, 2012
Our study identified nine loci newly associated with rheumatoid arthritis at a threshold of P < 5.0 × 10(-8), including B3GNT2, ANXA3, CSF2, CD83, NFKBIE, ARID5B, PDE2A-ARAP1, PLD4 and PTPN2.
Genetic variation in CD83 and risks of cervical and vulvar cancers: a population-based case-control study.
Schwartz et al., Seattle, United States. In Gynecol Oncol, 2012
Results do not suggest that the common genetic variation of CD83 is related to cervical or vulvar cancers. The association between tagSNP rs853360 and risk of cervical SCC is likely to be due to chance.
CD83-stimulated monocytes suppress T-cell immune responses through production of prostaglandin E2.
Zhang et al., Suzhou, China. In Proc Natl Acad Sci U S A, 2011
CD83-stimulated monocytes suppress T-cell immune responses through production of prostaglandin E2
Activated T cells induce rapid CD83 expression on B cells by engagement of CD40.
Breloer et al., Hamburg, Germany. In Immunol Lett, 2011
activated T cells induce CD83 on B cells via CD40 engagement but independent of TCR/MHC binding and thus independent of antigen-specificity of B cells.
Expression and distribution of S-100, CD83, and costimulatory molecules (CD80 and CD86) in tissues of thyroid papillary carcinoma.
Chen et al., Shantou, China. In Cancer Invest, 2011
Suggest that impaired immune function, absence of CD83-positive mature and activated dendritic cells in cancer nodules may have a role in the pathogenesis of thyroid papillary carcinoma.
CD83 increases MHC II and CD86 on dendritic cells by opposing IL-10-driven MARCH1-mediated ubiquitination and degradation.
Goodnow et al., Canberra, Australia. In J Exp Med, 2011
found that the transmembrane domain of CD83 enhances MHC class II and CD86 expression by blocking MHC class II association with the ubiquitin ligase MARCH1
Tumor-mediated liver X receptor-alpha activation inhibits CC chemokine receptor-7 expression on dendritic cells and dampens antitumor responses.
Russo et al., Milano, Italy. In Nat Med, 2010
In agreement with this observation, we detected CD83(+)CCR7(-) DCs within human tumors.
Differential gene expression patterns and interaction networks in BCR-ABL-positive and -negative adult acute lymphoblastic leukemias.
Sikic et al., Stanford, United States. In J Clin Oncol, 2007
This set of 271 differentially expressed genes (including GAB1, CIITA, XBP1, CD83, SERPINB9, PTP4A3, NOV, LOX, CTNND1, BAALC, and RAB21) is enriched for genes involved in cell death, cellular growth and proliferation, and hematologic system development and function.
Polyvalent dendrimer glucosamine conjugates prevent scar tissue formation.
Brocchini et al., London, United Kingdom. In Nat Biotechnol, 2004
Dendrimer glucosamine inhibited Toll-like receptor 4-mediated lipopolysaccharide induced synthesis of pro-inflammatory chemokines (MIP-1 alpha, MIP-1 beta, IL-8) and cytokines (TNF-alpha, IL-1 beta, IL-6) from human dendritic cells and macrophages but allowed upregulation of the costimulatory molecules CD25, CD80, CD83 and CD86.
share on facebooktweetadd +1mail to friends